Moderna‘s (NASDAQ:MRNA | MRNA Price Prediction) push into cancer treatment is drawing heavy buying as a closely followed ...
Moderna Inc. MRNA shares are trading higher Monday as investors position ahead of detailed Phase 3 melanoma data for its ...
It was a head-turning headline. Here's why the market was buzzing.
Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share ...
Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA ...
Following last month's super rally, a growing number of analysts are now calling for caution.
At the European Society of Medical Oncology meeting in Madrid this weekend, analysts will be watching for detailed data on ...
Moderna stock gains on reports of an initiative to accelerate cancer vaccine development. Here’s why caution is warranted in ...
The biotech giant posted positive trial results of a cancer vaccine, boosting shares at a record-setting pace before investors pulled back.
Moderna stock has rallied more than 200% since August, following positive Phase 3 trial results for a melanoma vaccine.
Moderna (MRNA) stock has gained 282.6% over the past three months, outpacing a 4.1% return for the S&P 500. The shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results